GlassScriptPhysician profile
Hong S Kim
NPI 1396727764
$20,947.81
in general payments reported to CMS, 2019-2025
56 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,486 · 2020: $2,919 · 2021: $4,182 · 2022: $2,992 · 2023: $2,915 · 2024: $2,303 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,290 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,289.65 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,440.59 | 2019-2025 | |
| Novo Nordisk INC | $1,660.45 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $1,465.92 | 2019-2025 | |
| Lilly USA, LLC | $1,308.46 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $1,112.74 | 2019-2025 | Evenity, Prolia, Otezla |
| Novartis Pharmaceuticals Corporation | $925.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $920.67 | 2019-2025 | Farxiga, Lokelma, Fasenra |
| Nestle Healthcare Nutrition INC. | $883.13 | 2020-2023 | |
| Astellas Pharma US INC | $845.13 | 2019-2024 | Veozah, Myrbetriq |
| Fresenius USA Marketing, INC. | $843.64 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.70 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $693.10 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $619.54 | 2024-2025 | Zenpep |
| Amarin Pharma, INC. | $581.55 | 2019-2022 | |
| Glaxosmithkline, LLC. | $557.06 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.